Regenerative Medical Technology Group Inc Financials
This page shows Regenerative Medical Technology Group Inc (RMTG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Regenerative Medical Technology Group Inc has an operating margin of 2.0%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 10/100, suggesting thin profitability after operating expenses. This is up from -29.7% the prior year.
Regenerative Medical Technology Group Inc's revenue surged 70.4% year-over-year to $4.1M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Regenerative Medical Technology Group Inc's current ratio of 0.04 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
Regenerative Medical Technology Group Inc converts 15.5% of revenue into free cash flow ($635K). This strong cash generation earns a score of 77/100.
Regenerative Medical Technology Group Inc scores -32.29, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($789K) relative to total liabilities ($31.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Regenerative Medical Technology Group Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Regenerative Medical Technology Group Inc generates $-0.15 in operating cash flow ($851K OCF vs -$5.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Regenerative Medical Technology Group Inc earns $0.0 in operating income for every $1 of interest expense ($81K vs $5.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Regenerative Medical Technology Group Inc generated $4.1M in revenue in fiscal year 2024. This represents an increase of 70.4% from the prior year.
Regenerative Medical Technology Group Inc's EBITDA was $302K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 174.5% from the prior year.
Regenerative Medical Technology Group Inc generated $635K in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 178.9% from the prior year.
Regenerative Medical Technology Group Inc reported -$5.6M in net income in fiscal year 2024. This represents an increase of 43.3% from the prior year.
Regenerative Medical Technology Group Inc earned $-0.44 per diluted share (EPS) in fiscal year 2024. This represents an increase of 44.3% from the prior year.
Regenerative Medical Technology Group Inc held $1.2M in cash against $0 in long-term debt as of fiscal year 2024.
Regenerative Medical Technology Group Inc had 13M shares outstanding in fiscal year 2024. This represents an increase of 0.4% from the prior year.
Regenerative Medical Technology Group Inc's gross margin was 68.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 0.8 percentage points from the prior year.
Regenerative Medical Technology Group Inc's operating margin was 2.0% in fiscal year 2024, reflecting core business profitability. This is up 31.7 percentage points from the prior year.
Regenerative Medical Technology Group Inc's net profit margin was -135.4% in fiscal year 2024, showing the share of revenue converted to profit. This is up 271.8 percentage points from the prior year.
Regenerative Medical Technology Group Inc invested $215K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 44.1% from the prior year.
RMTG Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M+20.0% | $984K-27.9% | $1.4M-9.7% | $1.5M+90.4% | $793K-2.9% | $817K+32.7% | $616K-4.8% | $647K |
| Cost of Revenue | $679K+70.7% | $398K-5.4% | $420K-20.8% | $531K+99.2% | $266K+7.4% | $248K+37.2% | $181K-8.0% | $197K |
| Gross Profit | $502K-14.4% | $586K-37.9% | $944K-3.7% | $980K+86.0% | $527K-7.4% | $569K+30.9% | $435K-3.5% | $450K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $278K+33.9% | $207K-15.5% | $246K+117.1% | $113K-56.8% | $262K+64.7% | $159K-57.4% | $374K+154.0% | $147K |
| Operating Income | -$446K-78.2% | -$250K-285.3% | $135K-64.5% | $381K+277.9% | -$214K-103.6% | -$105K | N/A | N/A |
| Interest Expense | $3.5M+230.8% | $1.1M+18.1% | $894K-12.3% | $1.0M-45.2% | $1.9M+0.4% | $1.9M | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.4M-233.4% | -$1.3M-71.8% | -$760K-19.1% | -$638K+69.3% | -$2.1M-5.9% | -$2.0M-665.9% | -$256K+95.6% | -$5.9M |
| EPS (Diluted) | $-0.35-250.0% | $-0.10-66.7% | $-0.06-50.0% | $-0.04+76.5% | $-0.17-6.3% | $-0.16-433.3% | $-0.03+93.6% | $-0.47 |
RMTG Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.5M+0.7% | $4.5M+12.7% | $4.0M+4.2% | $3.8M+25.3% | $3.1M-0.9% | $3.1M+6.9% | $2.9M-13.1% | $3.3M |
| Current Assets | $1.5M-21.0% | $1.9M+31.9% | $1.4M+16.1% | $1.2M+81.8% | $687K+2.7% | $668K+16.2% | $575K-51.7% | $1.2M |
| Cash & Equivalents | $1.2M-26.5% | $1.6M+32.0% | $1.2M+4.9% | $1.2M+88.9% | $617K+6.5% | $579K+9.2% | $531K-53.6% | $1.1M |
| Inventory | $156K+47.5% | $106K+363.0% | $23K+125.7% | $10K+51.4% | $7K | N/A | N/A | N/A |
| Accounts Receivable | $114K | N/A | N/A | $23K | N/A | N/A | N/A | N/A |
| Goodwill | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M0.0% | $1.7M |
| Total Liabilities | $34.6M+3.2% | $33.5M+4.4% | $32.1M+2.9% | $31.2M+7.9% | $28.9M+7.6% | $26.8M+8.8% | $24.7M-0.7% | $24.9M |
| Current Liabilities | $17.3M-43.4% | $30.5M+2.2% | $29.9M+3.1% | $29.0M+9.7% | $26.4M+8.5% | $24.4M+9.5% | $22.2M-8.9% | $24.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$30.1M-3.6% | -$29.0M-3.2% | -$28.1M-2.8% | -$27.4M-5.9% | -$25.8M-8.7% | -$23.8M-9.0% | -$21.8M-1.2% | -$21.5M |
| Retained Earnings | -$74.0M-6.3% | -$69.6M-1.9% | -$68.3M-1.1% | -$67.6M-2.3% | -$66.0M-3.2% | -$64.0M-3.2% | -$62.0M-0.4% | -$61.7M |
RMTG Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$204K+65.9% | -$598K-1147.3% | $57K-84.9% | $379K+319.7% | $90K-16.3% | $108K+467.2% | -$29K-390.0% | $10K |
| Capital Expenditures | $225K | N/A | N/A | $50K-5.0% | $53K-11.0% | $59K-79.2% | $284K+210.8% | $91K |
| Free Cash Flow | -$429K | N/A | N/A | $329K+772.8% | $38K-22.7% | $49K+115.6% | -$313K-285.7% | -$81K |
| Investing Cash Flow | -$225K | N/A | N/A | -$50K+5.0% | -$53K+11.0% | -$59K+79.2% | -$284K-210.8% | -$91K |
| Financing Cash Flow | $0 | N/A | N/A | N/A | N/A | N/A | -$300K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RMTG Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 42.5%-17.1pp | 59.6%-9.6pp | 69.2%+4.3pp | 64.9%-1.5pp | 66.4%-3.2pp | 69.6%-1.0pp | 70.6%+1.0pp | 69.6% |
| Operating Margin | -37.8%-12.3pp | -25.4%-35.3pp | 9.9%-15.3pp | 25.2%+52.2pp | -27.0%-14.1pp | -12.9% | N/A | N/A |
| Net Margin | -368.8%-236.0pp | -132.8%-77.1pp | -55.7%-13.5pp | -42.2%+219.5pp | -261.8%-21.7pp | -240.0%-198.4pp | -41.6%+863.9pp | -905.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -96.3%-67.2pp | -29.1%-10.0pp | -19.1%-2.4pp | -16.7%+51.4pp | -68.1%-4.4pp | -63.7%-54.8pp | -8.9%+167.8pp | -176.7% |
| Current Ratio | 0.09+0.0 | 0.06+0.0 | 0.050.0 | 0.04+0.0 | 0.030.0 | 0.030.0 | 0.03-0.0 | 0.05 |
| Debt-to-Equity | -1.150.0 | -1.15-0.0 | -1.140.0 | -1.14-0.0 | -1.12+0.0 | -1.130.0 | -1.13+0.0 | -1.15 |
| FCF Margin | -36.3% | N/A | N/A | 21.8%+17.0pp | 4.8%-1.2pp | 6.0%+56.9pp | -50.9%-38.4pp | -12.6% |
Note: Shareholder equity is negative (-$27.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Regenerative Medical Technology Group Inc's annual revenue?
Regenerative Medical Technology Group Inc (RMTG) reported $4.1M in total revenue for fiscal year 2024. This represents a 70.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Regenerative Medical Technology Group Inc's revenue growing?
Regenerative Medical Technology Group Inc (RMTG) revenue grew by 70.4% year-over-year, from $2.4M to $4.1M in fiscal year 2024.
Is Regenerative Medical Technology Group Inc profitable?
No, Regenerative Medical Technology Group Inc (RMTG) reported a net income of -$5.6M in fiscal year 2024, with a net profit margin of -135.4%.
What is Regenerative Medical Technology Group Inc's earnings per share (EPS)?
Regenerative Medical Technology Group Inc (RMTG) reported diluted earnings per share of $-0.44 for fiscal year 2024. This represents a 44.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Regenerative Medical Technology Group Inc's EBITDA?
Regenerative Medical Technology Group Inc (RMTG) had EBITDA of $302K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Regenerative Medical Technology Group Inc's gross margin?
Regenerative Medical Technology Group Inc (RMTG) had a gross margin of 68.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Regenerative Medical Technology Group Inc's operating margin?
Regenerative Medical Technology Group Inc (RMTG) had an operating margin of 2.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Regenerative Medical Technology Group Inc's net profit margin?
Regenerative Medical Technology Group Inc (RMTG) had a net profit margin of -135.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Regenerative Medical Technology Group Inc's free cash flow?
Regenerative Medical Technology Group Inc (RMTG) generated $635K in free cash flow during fiscal year 2024. This represents a 178.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Regenerative Medical Technology Group Inc's operating cash flow?
Regenerative Medical Technology Group Inc (RMTG) generated $851K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Regenerative Medical Technology Group Inc's total assets?
Regenerative Medical Technology Group Inc (RMTG) had $3.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Regenerative Medical Technology Group Inc's capital expenditures?
Regenerative Medical Technology Group Inc (RMTG) invested $215K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How many shares does Regenerative Medical Technology Group Inc have outstanding?
Regenerative Medical Technology Group Inc (RMTG) had 13M shares outstanding as of fiscal year 2024.
What is Regenerative Medical Technology Group Inc's current ratio?
Regenerative Medical Technology Group Inc (RMTG) had a current ratio of 0.04 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Regenerative Medical Technology Group Inc's debt-to-equity ratio?
Regenerative Medical Technology Group Inc (RMTG) had a debt-to-equity ratio of -1.14 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regenerative Medical Technology Group Inc's return on assets (ROA)?
Regenerative Medical Technology Group Inc (RMTG) had a return on assets of -145.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Regenerative Medical Technology Group Inc's debt-to-equity ratio negative or unusual?
Regenerative Medical Technology Group Inc (RMTG) has negative shareholder equity of -$27.4M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Regenerative Medical Technology Group Inc's Altman Z-Score?
Regenerative Medical Technology Group Inc (RMTG) has an Altman Z-Score of -32.29, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Regenerative Medical Technology Group Inc's Piotroski F-Score?
Regenerative Medical Technology Group Inc (RMTG) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regenerative Medical Technology Group Inc's earnings high quality?
Regenerative Medical Technology Group Inc (RMTG) has an earnings quality ratio of -0.15x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regenerative Medical Technology Group Inc cover its interest payments?
Regenerative Medical Technology Group Inc (RMTG) has an interest coverage ratio of 0.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Regenerative Medical Technology Group Inc?
Regenerative Medical Technology Group Inc (RMTG) scores 47 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.